Follicular thyroid lesions, elements that affect both diagnosis and prognosis

Journal of Surgical Oncology

Volumn 89, Issue 3, 2005, Pages 108-113

  Zeiger, Martha A ^a,b   Dackiw, Alan P B ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NONE   (United States)

Author keywords

Diagnosis; Follicular; Prognosis; Thyroid

Indexed keywords

CALCITONIN; NUCLEOSIDE DIPHOSPHATE KINASE A; RADIOACTIVE IODINE; THYROGLOBULIN;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; THYROID ADENOMA; THYROID CARCINOMA; THYROID SURGERY; THYROIDECTOMY;

EID: 14644398582     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20186     Document Type: Review

References (52)

1. LiVolsi VA, Asa SL: The demise of follicular carcinoma of the thyroid gland. Thyroid 1994;4:233-236.
2. Baloch ZW, LiVolsi VA: Follicular-patterned lesions of the thyroid: The bane of the pathologist. Am J Clin Pathol 2002;117:143-150.
3. LiVolsi VA: Can we agree to disagree? Hum Pathol 2003;34:1081-1082.
4. Li S, Baloch ZW, Tomaszewski JE, et al.: Worrisome histologic alterations following fine-needle aspiration of benign parotid lesions. Arch Pathol Lab Med 2000;124:87-91.
5. LiVolsi VA, Merino MJ: Worrisome histologic alterations following fine-needle aspiration of the thyroid (WHAFFT). Pathol Annu 1994;29:99-120.
6. Renshaw AA, Gould EW: Why there is the tendency to " overdiagnose" the follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 2002;117:19-21.
7. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
8. Cady B: Hayes Martin lecture. Our AMES is true: How an old concept still hits the mark: Or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462-468.
9. AACE/AAES: Medical/surgical guidelines for clinical practice: Management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001;7:202-220.
10. Chan JK: Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 2002;117:16-18.
11. Perrier ND, Ituarte PH, Treseler P, et al.: Classification and treatment of follicular thyroid neoplasms are discordant between and within medical specialties. Surgery 1999;126:1063-1068; discussion 1069.
12. Franc B, de la Salmoniere P, Lange F, et al.: Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 2003;34:1092-1100.
13. Segev DL, Umbricht C, Zeiger MA: Molecular pathogenesis of thyroid cancer. Surg Oncol 2003;12:69-90.
14. Tzen CY, Huang YW, Fu YS: Is atypical follicular adenoma of the thyroid a preinvasive malignancy? Hum Pathol 2003;34:666-669.
15. Fagin JA: Minireview: Branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 2002;16:903-911.
16. Segev DL, Clark DP, Zeiger MA, et al.: Beyond the suspicious thyroid fine needle aspirate. A review. Acta Cytol 2003;47:709-722.
17. Bartolazzi A, Gasbarri A, Papotti M, et al.: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-1650.
18. Cohen Y, Rosenbaum E, Clark DP, et al.: Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: A potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004;10:2761-2765.
19. Umbricht CB, Saji M, Westra WH, et al.: Telomerase activity: A marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 1997;57:2144-2147.
20. Cheung L, Messina M, Gill A, et al.: Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2003;88:354-357.
21. Nikiforova MN, Lynch RA, Biddinger PW, et al.: RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003;88:2318-2326.
22. Hay ID, Grant CS, Taylor WF, et al.: Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1095.
23. Woolner LB, Beahrs OH, Black BM, et al: Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg 1961;102:354-387.
24. Cady B: Presidential address: Beyond risk groups - A new look at differentiated thyroid cancer. Surgery 1998;124:947-957.
25. Mazzaferri EL: Long-term outcome of patients with differentiated thyroid carcinoma: Effect of therapy. Endocr Pract 2000;6:469-476.
26. AACE/AAES: Medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001;7:202-220.
27. Hay ID, Bergstralh EJ, Goellner JR, et al.: Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-1057; discussion 1057-1058.
28. Hay ID, Grant CS, Bergstralh EJ, et al.: Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958-964; discussion 956-964.
29. Byar DP, Green SB, Dor P, et al.: A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979;15:1033-1041.
30. Beahrs OH, Woolner LB: The treatment of papillary carcinoma of the thyroid gland. Surg Gynecol Obstet 1959;108:43-48.
31. Cady B, Rossi R: An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-953.
32. Shaha AR, Loree TR, Shah JP: Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995;118: 1131-1136; discussion 1136-1138.
33. Loh KC, Greenspan FS, Gee L, et al.: Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:3553-3562.
34. Sherman SI, Brierley JD, Sperling M, et al.: Prospective multicenter study of thyrois carcinoma treatment: Initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012-1021.
35. Wu HS, Young MT, Ituarte PH, et al.: Death from thyroid cancer of follicular cell origin. J Am Coll Surg 2000;191:600-606.
36. D'Avanzo A, Treseler P, Ituarte PH, et al.: Follicular thyroid carcinoma: Histology and prognosis. Cancer 2004;100:1123-1129.
37. Davis NL, Bugis SP, McGregor GI, et al.: An evaluation of prognostic scoring systems in patients with follicular thyroid cancer. Am J Surg 1995;170:476-480.
38. Emerick GT, Duh QY, Siperstein AE, et al.: Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer 1993;72:3287-3295.
39. Furlan JC, Bedard YC, Rosen IB: Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. J Am Coll Surg 2004;198:341-348.
40. Bullinger L, Dohner K, Bair E, et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605-1616.
41. Lapointe J, Li C, Higgins JP, et al.: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004;101:811-816.
42. van 't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
43. Mazzanti C, Zeiger MA, Costourous N, et al.: Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 2004;64:2898-2903.
44. Finley DJ, Arora N, Zhu B, et al.: Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004;89:3214-3223.
45. Cerutti JM, Delcelo R, Amadei MJ, et al.: A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 2004;113:1234-1242.
46. Zafon C, Obiols G, Castellvi J, et al.: nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:3975-3980.
47. Hedenfalk I, Ringner M, Ben-Dor A, et al.: Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 2003;100:2532-2537.
48. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
49. Armstrong SA, Staunton JE, Silverman LB, et al.: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30:41-47.
50. Golub TR, Slonim DK, Tamayo P, et al.: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999;286:531-537.
51. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
52. Sorlie T, Tibshirani R, Parker J, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.